AbaloparatidePTH-related peptide analogue
Abaloparatide is an osteoporosis medicine that stimulates bone formation. The relevant benefit is fewer fractures in people at increased risk, rather than a higher bone-density number in isolation.
What is Abaloparatide?
Abaloparatide is a parathyroid hormone-related protein analogue. EU Eladynos is indicated for osteoporosis in postmenopausal women at increased fracture risk. 4
How it works
Intermittent activation of the PTH1 receptor stimulates bone formation. This differs from maintaining a continuously elevated parathyroid-hormone signal.
Effects studied
Vertebral fractures
The EMA assessment reports fewer new vertebral fractures with abaloparatide than with placebo in the studied osteoporosis population. 4
Evidence: Clinical fracture evidence in a defined population; not a general bone-strength supplement claim.
What does the evidence show?
Osteoporosis trials and EMA product assessment
A signal to bone-forming cells
Abaloparatide resembles part of parathyroid hormone-related protein and acts at the PTH1 receptor. Its intermittent action encourages bone formation. This distinguishes it from medicines whose main role is slowing bone breakdown, although both approaches can be used in osteoporosis care.
What the trials measured
Osteoporosis trials assess bone density and fractures, which answer related but different questions. The EMA assessment reports fewer new vertebral fractures with abaloparatide than placebo in the main study. The result applies to the women enrolled and the treatment period studied. It does not establish stronger bones for everyone. 4
Who the European assessment concerns
Eladynos is authorised in the EU for osteoporosis in postmenopausal women at increased fracture risk. Choosing a treatment still involves previous fractures, other illnesses and the plan for maintaining bone protection afterwards. Evidence for one osteoporosis medicine does not establish that it is best for every person. 4
Calcium and tolerability matter
Raised calcium in urine, dizziness and injection-site effects are among the concerns described by EMA. The decision depends on whether fracture protection outweighs the burdens of treatment for that person. Abaloparatide belongs in a structured osteoporosis plan, rather than a general nutrition or anti-ageing routine. 4
Safety & status
Raised urinary calcium, dizziness and injection-site reactions are among the relevant adverse effects described in the EMA information. 4
Country and product status
EU Eladynos indication checked: postmenopausal osteoporosis with increased fracture risk. Swiss status not checked.
Frequently asked questions
Is it used for anyone with low bone density?
Its indication is narrower: postmenopausal osteoporosis with increased fracture risk, subject to the product’s eligibility criteria. 4
Is increased bone density the only outcome studied?
No. New vertebral fractures were also assessed, providing an outcome beyond a scan measurement. 4
Further reading
Sources
This entry was rewritten from our research archive. References below are reading leads unless a completed check is explicitly noted; a full independent evidence and regulatory review is still pending.
- Retained paper reference Archive research lead · Retained archive reference; not independently checked for this draft
- Retained paper reference Archive research lead · Retained archive reference; not independently checked for this draft
- Retained source reference Archive research lead · Retained archive reference; not independently checked for this draft
- EMA · Eladynos assessment Primary source checked · Checked 27 October 2026: EU indication, mechanism, fracture findings and principal safety information.
Research provenance
This name was discovered in the Superpower peptide index, archived 26 October 2026. Its ratings and reviewer attribution have not been adopted as our own. The archive informed this original editorial draft; independent source review is still pending.